How will the federal government determine whether people who receive the 2009 H1N1 vaccine have an increased risk for Guillain-Barré syndrome (GBS)?
CDC, FDA, and other federal agencies are tracking GBS through VAERS and several other safety monitoring systems. In VAERS, scientists will assess whether reports of GBS are more common among reports received for H1N1 vaccine compared to seasonal flu vaccine or other vaccines. At the same time, CDC and others are working with neurologists, the medical specialists who see most GBS cases, to encourage reporting of GBS cases through VAERS. Another system tracking GBS is the Vaccine Safety Datalink project, or VSD. Analysis of VSD information will determine if GBS is more common among people who have received H1N1 vaccine than among people that have not received it. CDC, in collaboration with neurologists, academic centers and state health departments, is also tracking GBS disease among persons in 10 states who are part of CDC’s Emerging Infections Program. If there is an increase in the number of reported cases, public health officials will conduct intensive investigations. If any problems
Related Questions
- How will the federal government determine whether people who receive the 2009 H1N1 vaccine have an increased risk for Guillain-Barré syndrome (GBS)?
- How will the federal government determine whether people who receive the 2009 H1N1 vaccine have an increased risk for GBS?
- Why are some people at increased risk of severe illness from H1N1 influenza 09 this winter?
